Tetragram, a cannabis technology company, is partnering with the CannabisEducation and Research Institute (CERI) to conduct a wide-ranging research survey intothe medicinal uses, doses, routes of administration, and potential side effects of cannabis.
The research relies on an anonymous survey that asks cannabis users about cannabisstrains, specific products, and the botanical’s medicinal uses.
“Federal regulations have made cannabis research in the United States almost nonexistent.That’s why this research is so important,” said Otha Smith, III, CEO of Tetragram. “Cannabisusers have largely relied on a frustrating trial-by-error process to find the most effectiveproducts for their conditions. We need more product-specific research.”
The research will provide valuable information to cannabis users as well as to cannabisdispensaries and growers who can create and sell products that better align with the needsof patients and cannabis users.
Smith called CERI the right partner for the research. “We can help patients obtain betterinsights and better buying decisions,” Smith said.
CERI CEO David Knowlton said people using cannabis for medical conditions such aschronic pain, anxiety, cancer, epilepsy, and other conditions need greater insight andguidance.
“All cannabis is not the same — and patients need information to guide them to the rightstrain and dosage for their condition. The Tetragram community will help us createresearch valuable to all cannabis users,” Knowlton said.
The principal investigator of the research is Sandy Gibson, PhD., MSW, a researcher andprofessor at The College of New Jersey. The research will collect information aboutterpenes and cannabinoids, both compounds that are abundant in the cannabis plant andhave different effects.
Tetragram is a free, private, and secure mobile app that enables cannabis and CBDconsumers to track the products they purchase, rate the effectiveness of products, andshare their reviews with a cannabis community. Current Tetragram users will receive anemail inviting them to participate in the 8-minute, confidential survey. New users will beasked to participate as they sign up for the Tetragram app. The survey is completelyvoluntary and will not be linked to the data in the users’ Tetragram app. Declining toanswer the survey will not affect use of the app in any way.
The creation of Tetragram was inspired by Smith’s recuperation after he nearly died ina 2006 car accident. Concerned about continuing to take the opioids he was prescribedfor pain, Smith turned to cannabis. He found it challenging, though, to find and thenremember the strains that were most effective for his different types of pain.
Smith created Tetragram to enable cannabis users to journal and share theirexperiences.
CERI works to advance unbiased medical research and credible information aboutmedicinal cannabis. Before leading CERI, Knowlton founded the Compassionate CareFoundation, an alternative treatment center that dispensed medicinal cannabis in EggHarbor Township from 2013 until 2020. He worked with medicinal patients and sawfirsthand how cannabis helped patients.
“The survey is voluntary and anonymous. But I would say that in our experience,cannabis users are generally happy to share their best practices with others,” saidKnowlton. “We believe patient experiences are essential to cannabis research, and weare pleased to begin this partnership with Tetragram.”
ABOUT TETRAGRAMTetragram is SAAS platform based in Baltimore, MD. Tetragram’s mission is to empowercannabis and CBD consumers with the ability to Track, Rate, and Share their personalexperiences with others. In addition, Tetragram partners with dispensaries, wholesalers, andthe medical community to provide a clear understanding of the impact of cannabis and CBDuse and the ability to connect directly to consumers. More information is availableat Tetragramapp.com.
ABOUT CERIThe Cannabis Education and Research Institute is a non-profit organization based inPennington, New Jersey. CERI’s goal is to advance accessibility of medicinal cannabis throughunbiased, evidenced-based research provided to consumers, clinicians, payers and policymakers so they can make informed decisions about cannabis. More information is available atCERIUSA.org